Semaglutide shows cardiovascular benefits beyond weight loss

12 articles · Updated · Vocal · Apr 28

Researchers say clinical-trial data indicate Wegovy and Ozempic can cut heart-attack and other cardiovascular-event risk, potentially widening interest in GLP-1 medicines beyond current obesity-treatment use.
The reported benefits may stem from improved fatty-acid metabolism and reduced inflammation, suggesting these drugs act on multiple body systems rather than simply lowering weight.
Experts say it is too early to recommend them for people who are not overweight, and current prescribing guidance generally limits anti-obesity drugs to higher-BMI patients or those with related conditions.

If these drugs protect hearts regardless of weight, could they soon become a preventative medicine for people without obesity?

Weight loss drugs now reduce heart attack risk. Are we trading obesity for lifelong drug dependency and hidden health costs?

Oral weight loss pills are now available. How will this easier access reshape our views on body weight, effort, and healthcare?